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Abstract
The differentiation stage of tumors is a central aspect in the histopathological classiﬁcation of solid malignancies. The
differentiation stage is strongly associated with tumor behavior, and generally an immature tumor is more aggressive than
the more differentiated counterpart. While this is common knowledge in surgical pathology, the contribution of
differentiation-related gene expression and functions to tumor behavior is often overlooked in the experimental, tumor
biological setting. The mechanisms by which tumor cell differentiation stages are perturbed or affected are poorly explored
but have recently come into focus with the introduction.of the tumor stem cell concept. While developmental biologists
view the differentiation as a unidirectional event, pathologists and tumor biologists have introduced the concept of
dedifferentiation to explain phenotypic changes occurring in solid tumors. In this review we discuss the impact of the tumor
cell differentiation stage as used in surgical pathology. We further discuss knowledge gained from exploring the molecular
basis of the differentiation and dedifferentiation processes in neuroblastoma and breast cancer, two tumor forms where
the tumor cell differentiation concept is used in the clinical diagnostic work and where the tumor stem cell theory has been
applied.
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Introduction
The biological meaning of the term differentiation
denotes the developmental process whereby cells grad-
ually acquire the capacity for a more specialized func-
tion by change of phenotype. While developmental
biologists generally view this process as unidirectional,
observations in the context of cancer show that the
differentiation process can reverse and that cells can
dedifferentiate. Despite the fact that classical tumor
diagnostics based on surgical pathology and histology
for decades have used tumor cell differentiation status
as one important aspect to score, evaluate, and com-
municate tumor aggressiveness, overall experimental
tumor biology has over the years not focused on the
differentiation processes, but rather studied molecular
pathways leading to growth, migration, and cell death.
However, the rapid and recent development of stem
cell as well as tumor stem cell research have galvanized
the study of the differentiation processes in cancer,
which has provided insights into the cellular and
molecular biological underpinnings of cancer-driven
mechanismsleadingtochangesinthedegreeofcellular
differentiation or dedifferentiation. In this contribution
we discuss the impact of the tumor cell differentiation
stage on tumor behavior and the use of this important
concept in surgical pathology. We further summarize
knowledge gained from exploring the differentiation
and dedifferentiation processes in two tumor forms,
neuroblastoma and breast cancer.
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In the realm of surgical pathology, the concept of
cellular differentiation is made very concrete although
used from a different angle and with a somewhat
different content than its usage in developmental
biology. Apart from performing the obvious task of
ruling out/determining whether a tumor is malignant
or benign, the pathologist also most often evaluates
malignancies aiming to assess their degree of differ-
entiation, implying that neoplastic cells have the
potential to slide back along the line of differentiation.
The result has prognostic implications where, as a
rule, a high degree of differentiation purports a better
prognosis than a low degree. Using morphological
criteria, the degree of resemblance between the neo-
plasia and its tissue of origin is gauged. A high degree
of differentiation means that the neoplasia is morpho-
logically similar to the native organ, forming neoplas-
tic organoid structures, whereas the opposite is true
for a low stage of differentiation, where cells gradually
lose the capacity for structural organization and start
to display reduced cohesiveness and where the term
anaplasia denotes tumor morphology where all sim-
ilarity with the origin has been lost.
The results from evaluating the degree of differ-
entiation are often presented using a two- or three-
tiered scale as exempliﬁed by the common skin
malignancy, squamous cell carcinoma (SCC). If a
case of SCC grows in an outward (verrucous) fash-
ion, still maintains keratin-forming capacity, has
cells with ample cytoplasm, only slight nuclear aty-
pia, and only few mitotic ﬁgures, it is regarded as
highly differentiated. This means that no signs of
invasion below the basal membrane are seen and
metastatic disease is rare. On the other side of the
scale is the SCC of low differentiation, where cells
growin sheets and with no signs ofkeratin formation.
In these cases the mitotic index is often high, and
occasionally immunohistochemistry has to be used
to conclude that this cancer indeed is derived from
the squamous epithelium. Biologically, these poorly
differentiated cancers often invade deeply through
the dermis and have a bad prognosis with a propen-
sity for lymph node metastasis. In between these
poles are the intermediately differentiated cases of
SCC.
Another pertinent example of how differentiation
s t a g i n gi su s e di nm o d e r ns u r g i c a lp a t h o l o g yi st h e
Gleason scoring system developed for prostate can-
cer. Neoplastic prostate glands are here judged for
their capacity to form glandular structures. Grades
1 and 2 are similar to native glands, whereas
grade 3 demonstrates glands of reduced diameter
growing as separate units in the prostatic tissue, still
respecting other glands, malignant as well as benign.
Grade 4 heralds that the malignant glands start to
coalesce and fuse, whereas grade 5 show malignant
cells growing either in sheets or as single cell units,
totally devoid of gland-forming capacity. To arrive at
the Gleason score, the grade of the most commonly
seen cancer (e.g. 3) is added to that of the minority
pattern (e.g. 4), which gives a Gleason score of 7. In
this case a composite score based on the degree of
dedifferentiation is used, which has contributed sig-
niﬁcantly to the prognostic power of the Gleason
grading system.
The morphological correlates of dedifferentiation
have been known to pathologists for over a century,
but an explanation of the mechanistic factors behind
this process has been lacking and unexplored until
recent times when the armamentarium of cellular
and molecular tumor biology has been deployed to
study this phenomenon. A process of interest in this
context is the epithelial to mesenchymal transition
(EMT). This term describes how epithelial cells
phenotypically transdifferentiate towards a more mes-
enchymal/ﬁbroblastoid/spindle-shaped cell, simulta-
neously gaining increased capacity for invasiveness
and motility. An important question in this context is
to what degree EMT equates to dedifferentiation.
Addressing this issue, it is important to remember
that, by deﬁnition, carcinomas develop from epithelial
cells. Epithelial cells, however, are not deﬁned at a
cellular but at an architectural level, where epithelial
cells form multidimensional cohesive cellular sheets
of varying thickness resting upon the basal lamina,
resulting functionally in immobile cells. The mesen-
chymal cell, on the other hand, is deﬁned at a cellular
level, being spindle-shaped, bipolar, and motile.
These cellular categories are the two prototypic cells
of chordates (1) from embryogenesis and onwards.
Actually, the co-ordinated actions of these dual cell
types form the very basis for development of
higher life forms, above the level of amphioxi, under-
scoring their fundamental developmental importance.
With this deﬁnition in mind the terms dedifferentia-
tion and EMT show a considerable degree of con-
ceptual overlap. Although implicated during invasion,
intravasation, and metastasis, clear-cut examples of
clinically relevant EMT in cancers have been hard to
demonstrate, even if attempts have been made (2).
However, as pointed out, dedifferentiated tumors
indeed have a considerably worse prognosis, and
this category is more often found to invade vascular
and neural structures and transgress histological
boundaries such as organ capsules, which micro-
scopically recapitulates the in vitro data on cells
performing EMT.
218 A. Jögi et al.Neuroblastoma and tumor cell differentiation
There are few tumor forms that present such a tight
link between clinical behavior and tumor cell differ-
entiation stage as the childhood cancer neuroblas-
toma. Being derived from sympathetic nervous
system precursor cells or immature neuroblasts, neu-
roblastoma cells are arrested at varying stages of
differentiation, and, based on histopathology and
degree of morphological differentiation, three tumor
variants have been deﬁned: 1) the benign ganglio-
neuromas exclusively containing ganglion-like cells
and stroma, 2) ganglioneuroblastomas containing
neuroblast-like immature cells with small nuclei
and scant cytoplasms intermixed with a smaller or
larger proportion of more differentiated tumor cells
with larger nucleus and cytoplasm, and 3) neuroblas-
toma proper with neuroblast-like cells and lacking
tumor cells that show apparent signs of morphological
ganglionic differentiation. More intriguing, neuro-
blastomas show one of the highest rates of spontane-
ous differentiation, a phenomenon ﬁrst reported in
1927 by Cushing and Wolbach who described a child
with a sympaticoblastoma (later termed neuroblas-
toma) that spontaneously developed into a more
differentiated, non-aggressive tumor with a differen-
tiated sympathetic phenotype (3). At the molecular
level, the association between high expression of sym-
pathetic ganglionic marker genes and favorable dis-
ease was established 80 years later based on global
gene expression analyses (4). Through the pioneering
work by June Biedler, Robert Seeger, and others,
neuroblastoma was one of the ﬁrst human tumors
to be established in culture, and some of these cell
lines were shown to have retained the capacity to
differentiate along a ganglionic lineage in vitro in
response to external stimuli such as phorbol esters
and retinoic acid (5,6). These ﬁndings suggested that
aggressive neuroblastomas might become treatable by
inducing a differentiation response as part of the
treatment protocol. Today 13-cis-retinoic acid at
pharmacological levels is used as adjuvant treatment
following myeloablative therapy; whether the
observed clinical effects are related to retinoic acid-
induced changes in the stage of tumor cell differen-
tiation has not been established.
Neuroblastoma and phenotypic heterogeneity
In a subset of neuroblastomas, tumor cells are orga-
nized in lobular structures with zones of necrotic cells
in the lobule center (7). In these lobules a neuronal-
to-neuroendocrine lineage conversion occurs with the
neuroendocrine cells located adjacent to the necrosis
(8). The sympathetic nervous system lineage markers
used in these studies could not distinguish between
sympathetic paraganglionic and sympathetic SIF
(small intensely ﬂuorescent) phenotypes. Hence,
the exact nature of the neuroendocrine cells detected
in lobular neuroblastomas has not been established,
although the adrenal chromafﬁn marker gene PNMT
is not expressed, ruling out a neuroblastoma-to-
pheochromocytoma conversion pathway. These old
data exemplify the frequently occurring intra-tumoral
phenotypic heterogeneity in solid cancers and do
suggest that such heterogeneity is not exclusively a
result of mosaicism of genetic aberrations. Our
data further imply the existence of intra-tumoral
mechanisms regulating the differentiation stage of
tumor cells.
Hypoxia promotes an immature, stem
cell-like neuroblastoma phenotype
Concurrently with our report that peri-necrotic neu-
roblastoma cells differ in phenotype compared to cells
located closer to the ﬁbrovascular stroma, the corre-
lation between tumor hypoxia and aggressive disease
was demonstrated (9), and the molecular basis for
cellular adaptation to hypoxia began to be resolved.
Semenza and co-workers identiﬁed hypoxia inducible
factor HIF-1 (10), which together with HIF-2 is the
central transcription factor governing cellular adap-
tation to hypoxia (11). These dimeric transcription
factors have a b-subunit (also called ARNT) in com-
mon and an oxygen-sensitive a-subunit unique for
HIF-1 and HIF-2, respectively. At hypoxia the
a-subunits become stabilized, transported into the
nucleus to dimerize with ARNT, and by additional
mechanisms activated to induce the transcription of a
number of hypoxia-driven genes (12). Based on the
potential impact by which the HIF transcription fac-
tors can affect the tumor cell phenotype, we asked if
hypoxic cells of established neuroblastoma cell lines
gained a neuroendocrine phenotype similar to that of
peri-necrotic, lobular, neuroblastoma cells. As
reported, none of the tested cell lines showed a
hypoxia-induced neuronal-to-neuroendocrine lineage
shift, but instead hypoxia promoted an immature,
neural crest-like phenotype (13,14). As classical neu-
roblastoma cell lines are all derived from high-stage,
most often MYCN-ampliﬁed tumors, and not tumors
of the lobular type described above, our current
hypothesis is that we did not use the adequate cells
for testing in vitro the capacity of lobular neuroblas-
toma cells to convert into a neuroendocrine cell under
hypoxic conditions. The important outcome of these
experiments was the observation that hypoxia can
dedifferentiate tumor cells, a ﬁnding now corrobo-
rated in many different tumor forms (15), including
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provides one mechanism behind phenotypic hetero-
geneity in solid tumors and, importantly, highlights
how hypoxia can contribute to the aggressive behavior
of tumors with an overall low grade of oxygenation.
HIF-2a-deﬁned pseudohypoxic phenotype and
tumor aggressiveness in neuroblastoma
According to well-established models, both HIF-1a
and HIF-2a subunits become degraded via the
proteasomes’ conditions of proper oxygenation
(16). However, in clinical samples we found that
HIF-2a but not HIF-1a protein was highly expressed
in a small subset of neuroblastoma cells close to blood
vessels (17-19). In cell lines we could establish that
HIF-2 was active at a subphysiological level of
oxygenation (5% oxygen) and transcribing known
hypoxia-driven genes such as VEGF. Importantly,
presence of tumor cells with strong immunohisto-
chemical staining for HIF-2a correlates to high
clinical neuroblastoma stage and unfavorable out-
come (17). A closer examination of the HIF-2a-
positive, peri-vascular cells revealed that they are
immature and have a neural crest-like phenotype
(18). They further express VEGF, and we specu-
late that this subset of tumor cells actively attracts
vascular endothelial cells. Glioma tumor stem/tumor-
initiating cells as deﬁned functionally are immature,
have neural stem cell properties, and express high
HIF-2a protein levels (20). Like the strongly HIF-2a
and VEGF-positive neuroblastoma cells, glioma stem
cells are located in a peri-vascular niche and express
VEGF (20). Thus, these two neutrally derived tumors
contain subsets of cells that are immature, and their
presence is associated with an aggressive, unfavorable
disease. HIF-2 appears to be involved in keeping the
stemness of both neuroblastoma and glioma cells,
and, as discussed below, HIF-2a expression in breast
cancer is also associated to unfavorable disease, sug-
gesting HIF-2a as a potential treatment target in these
tumor forms. As shown in neuroblastoma, by down-
regulating HIF-2a in stem cell-like cells, sympathetic
neuronal differentiation can be induced (21), and we
speculate that HIF-2 inhibition could be a strategy to
push immature stem cell-like cells into a more differ-
entiated, bulk-like cell population that can be treated
by established treatment protocols.
Breast cancer and tumor cell differentiation
Breast cancer is an additional tumor type where
impaired development is an important component
of the malignant process and where the tumor cell
differentiation stage is used in histopathological
tumor grading. The Nottingham grading system,
widely employed for diagnosis and prognosis of breast
tumors, is based on three parameters: extent of tubule
formation, mitosis frequency, and nuclear pleomor-
phism, where at least the ﬁrst and last elements are
related to differentiation stage. Tubule formation
requires presence of differentiated polarized epithelial
cells and that these cells orientate in relation to
adjacent cells. Thus, the capacity to form tubules
is indicative of the differentiation stage of a group
of breast cancer cells. In breast cancers cells are
unable to distinguish between apical and basal surface
and organize themselves into tubule-like organoid
structures, have a low stage of differentiation, and
receive a high score in the Nottingham grading
system. Increased nuclear-to-cytoplasmic ratio is
also a marker of low differentiation, and when it is
associated with variation in nuclear size between
cancer cells the tumor gets a high score also in this
element of the Nottingham grading system. A high
Nottingham score (8–9, or grade III) is associated
with poor prognosis and progressing disease. The
relation between differentiation stage and prognosis
in breast cancer implies that the understanding of
processes of cancer initiation and progression should
be paralleled by insight into mechanisms of normal
breast development and function.
The tissue origin in breast cancer, the mammary
gland, is continuously in a developmental phase in
fertile women. Puberty and pregnancy are phases of
intense epithelial cell growth, migration, and differ-
entiation. The life cycle of the mammary gland in
addition holds phases of epithelial regression and
tissue remodeling, i.e. the dramatic involution after
lactation and tissue regression after menopause. The
involution process involves extensive cell death in the
epithelial compartment, intense remodeling of the
stromal compartment, and inﬁltration of inﬂamma-
tory cells. In this apparently chaotic environment the
mammary epithelial tissue stem cells must be pre-
served to ensure rebuilding of the functional gland in
future pregnancies. All these processes of the mam-
mary gland functional cycle, proliferation, differenti-
ation, and regression also occur in each monthly
estrous cycle but to a lesser extent. There is a strong
correlation between the total number of estrous cycles
during lifetime (depending on early menarche, late
menopause, and number of child-births) and the risk
of breast cancer, implying that stem cell activation
and differentiation processes are linked to breast
tumorigenesis (22).
In breast ductal carcinoma in situ (DCIS) with
comedo lesions, layers of transformed epithelial cells
ﬁll up the ductal space and due to intra-lesional
hypoxia a central necrotic core arises (Figure 1A).
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and have increasing protein levels of e.g. HIF-1. We
have reported that the breast cancer cells close to the
necrotic core have a less differentiated phenotype as
assessed by histopathological criteria (23). The hyp-
oxic cells have increased nuclear-to-cytoplasmic ratio
and decreased expression of markers of differentia-
tion, including estrogen receptor (ER) in ER-positive
lesions. Furthermore, small duct-like structures fre-
quently form within DCIS lesions and represent
transformed epithelial cells striving to organize them-
selves into polarized epithelial structures, structures
that are rarely encountered in the hypoxic peri-
necrotic regions of the DCIS lesions. Thus, intra-
lesional hypoxia has direct bearing on two of the
elements of the Nottingham grading system, nuclear
phenotype and tubule formation. Our hypothesis
is that the hypoxic conditions lead to a less differen-
tiated tumor cell with lost ability to form organized
and polarized structures. In support of this hypo-
thesis, cells of established human breast cancer cell
lines cultured at hypoxic conditions showed down-
regulated expression of ER and up-regulation of
CK19, indicating that, both in vitro and in vivo,
hypoxic conditions promote a less differentiated
breast cancer phenotype (23).
DCIS is an instance of a typical carcinoma in situ
lesion where the basal membrane has not been
breached, meaning that the cancer is non-invasive.
Initially regarded as a fairly homogeneous disease
divided into non-comedo versus comedo type,
DCIS is now seen as a multi-faceted entity where
the degree of differentiation within the DCIS lesion
has a large impact on the outcome. Cases displaying
low differentiation most often progress to invasive
carcinoma, whereas cases of high differentiation are
less likely to do so. This underscores the importance
of assessing differentiation also in pre-invasive can-
cers. As a whole, DCIS may be seen as an interme-
diate step in the maligniﬁcation process of tumors,
and the typical hallmark trait of low differentiation in
this form of neoplasia is the presence of comedo-
type necrosis. This means that the cancer tissue has
a necrotic and hypoxic center. This implies that
hypoxia might contribute to the conversion of
DCIS cells into invading tumor cells. One question
we have addressed is whether the observed hypoxic
impairment of differentiation in DCIS lesions is
restricted to cancer cells. A related question is
whether hypoxia can arrest normal breast epithelial
cells at an immature differentiation stage and by
doing so contribute to onset of tumorigenesis. We
have studied the non-malignant immortalized mam-
mary epithelial MCF-10A cells in 3D cultures where
these cells form mammary acini with polarized rim
cells and evacuated lumen. Hypoxia impaired both
polarization and lumen formation as demonstrated in
MCF-10A cells (Figure 1B and C) (Vaapil et al.,
unpublished paper, 25). Furthermore, a fraction of
hypoxic MCF-10A cells remained in cell cycle, while
the vast majority of the normoxic cells entered a
differentiated post-mitotic state. Still the hypoxic
structures were smaller, which we could attribute
to increased apoptosis. We conclude that hypoxia
confers a cancer-like phenotype to the mammary
epithelial cells.
It is nowadays well established that intra-tumor
hypoxia correlates to a worse prognosis in many
A BC 21% 1% DCIS
Figure 1. A: Ductal carcinoma in situ of the breast, the comedo form, with several cell layers of epithelial cells surrounding a central necrotic
area. The inner cell layers, adjacent to the necrosis, show low differentiation with unorganized structures and increased nucleus-to-cytoplasm
ratio (scale bar: 500 mm). B: Non-malignant mammary epithelial cells cultured in a three-dimensional differentiation-inducing assay. After
21 days of culture at normoxia (21% O2), the mammary epithelial cells (MCF-10A) differentiate into growth-arrested, organized acini
structures with polarized cells surrounding a hollow lumen, resembling the in vivo mammary gland appearance. The differentiated mammary
cells have a polarized expression pattern of proteins, here laminin V (green), and small compact nuclei (blue, actin in red) in a palisade
structure. C: At hypoxia (1% O2) the MCF-10A mammary epithelial cells fail to arrange into organized structures and appear as cell aggregates
without lumen or polarized protein localization. The hypoxic cells have larger nuclei, remain proliferative, and express markers of
undifferentiated cell stage—characteristics often seen in breast carcinoma (scale bar: 20 mm).
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tumor protein levels of HIF-1 and HIF-2, respec-
tively, are also linked to poor patient outcome in
breast cancer (reviewed in (26)). In particular, we
have shown that HIF-2 protein accumulation corre-
lates to worse breast cancer speciﬁc survival and
distant metastasis (26). Formation of distant metas-
tases has been attributed to the presence of cancer
stem or tumor-initiating cells, and we speculate that
HIF-2 is a marker of such cell populations. The
nature of the breast cancer stem cell is still far from
established; the CD44
+/CD24
- phenotype reported
by Al-Hajj et al. (27) does not seem to be the exclusive
breast tumor-initiating cell totem. It has not been
established that breast tumor-initiating cells have
breast stem cell phenotype, and it has lately been
implied that stem cell-like cancer cells can arise
from more differentiated cells, e.g. through the pro-
cess of EMT (28). Hypoxia has been shown to induce
EMT in tumors (29) and may be one process wherein
breast cancer cells with stem cell properties arise. This
general differentiation-counteracting effect of hypoxia
has direct bearing on tumor aggressiveness, as tumors
with immature features are more aggressive than the
corresponding differentiated tumors.
Tumor cell differentiation/
dedifferentiation pathways in relation to
normal development
Tumor cells recapitulate morphology and central
gene expression proﬁles of non-malignant cells, which
is the basis for histopathological and immunohisto-
chemical classiﬁcation of solid tumors. The differen-
tiation traits, apparent or delicate, together with
location of the primary tumor, determine the histo-
pathological diagnosis. Both at the morphological and
molecular levels, the degree or stage of differentiation
of the tumor cells is estimated, and depending on the
outcome of these estimations tumors are often viewed
as being arrested at early or late stages of differenti-
ation. However, whether a given tumor cell differen-
tiation stage reﬂects a distinct stage during normal
development has to our knowledge not been studied
in any detail. Based on our own neuroblastoma data,
we would claim that this is not the case. While
normally developing human sympathetic neuro-
blasts appear to express a given set of genes in a
co-ordinated and repeated fashion between embryos
(30), only a subset of the same set of genes is usually
expressed in a given tumor, and this subset can differ
from one tumor to another and between tumor cells
within a tumor as exempliﬁed by the neuron-speciﬁc
enolase (ENO2) expression (in neuroblastoma and
ganglioma, the differentiated form of neuroblastoma)
(Figure 2) (31). Thus, we would like to claim
that differentiation pathways are disorganized in
neuroblastoma and that this aberrant differentiation
is a tumor characteristic. We hypothesize that this
might also be the case in many other tumor forms.
Similarly, when tumor cells dedifferentiate, do
they then play back and recapitulate in reverse the
developmental stages that once formed them? And
when for instance hypoxic cells developstem cell-like
phenotypes, do they indeed become stem cells?
These are central questions as they relate to the
concept of tumor stem cells or tumor-initiating cells.
Without formal proofs and experimental backup, we
assume that the stem cell phenotype of tumor cells
only mimics that of the cognate stem cell. However,
as demonstrated in glioma, the glioma stem cells
have the capacity of neural stem cells to give rise to
distinct non-glial differentiation lineages (32,33).
Thus, while the transcriptome of tumor stem cells
AB
Figure 2. Human neuroblastoma specimens stained for neuron-speciﬁc enolase by immunohistochemistry. Sections of a neuroblastoma bone-
marrow metastasis (A) and a ganglioneuroma specimen (B), respectively, stained for neuron-speciﬁc enolase (ENO2) expression. Note that
tumor cells differ considerably in neuron-speciﬁc enolase levels, both at a more immature (panel A) and at a differentiated (panel B) stage.
Arrows show enolase-positive and arrow-heads show enolase-negative tumor cells.
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pluripotent tumor cells with stem cell phenotype and
capacity probably contribute signiﬁcantly to the
phenotypic heterogeneity seen in solid cancers where
the EMT process perhaps is the most extensively
studied.
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